Physitrack Group
Investor Relations
Shaping the future of digital health by building value for key stakeholders through innovation and sustainable business management.
Recent reports and webcasts
Interim Report Q2 2026
1 January - 30 June 2026
From 2024 Annual Report
Key financial highlights
14
%
Year-on-year organic growth
€
1600
K
Total available liquidity
30
%
Operating cash flow (MSEK)
Physitrack Spotlight
Gain exclusive access to comprehensive insights that transcend conventional press releases through our Spotlight newsroom.
July 22, 2026
Redeye Q2 2026 CEO Interview
Details
Redeye's Jessica Grunewald interviews CEO Henrik Molin on Q2 results
